Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Date
2018
Author
Horneff, Gerd
Fischbach, Michel
Foster, Helen E.
Ruperto, Nicolino
Brunner, Hermine I.
Quartier, Pierre
Constantin, Tamas
Wulffraat, Nico M.
Schneider, Rayfel
Anton, Jordi
Barash, Judith
Berner, Reinhard
Corona, Fabrizia
Cuttica, Ruben
Fouillet-desjonqueres, Marine
Foell, Dirk
Radominski, Sebastiao C.
Ramanan, Athimalaipet V.
Trauzeddel, Ralf
Unsal, Erbil
Levy, Jeremy
Vritzali, Eleni
Martini, Alberto
Lovell, Daniel J.
Kasapcopur, Ozgur
Metadata
Show full item record
Abstract
Objectives To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA).
URI
http://hdl.handle.net/20.500.12627/141163
https://doi.org/10.1136/annrheumdis-2018-213150
Collections